Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

被引：0
|
作者：
Starodub, Alexander N. [1 ]
Ocean, Allyson J. [2 ]
Guarino, Michael J. [3 ]
Chuang, Ellen [2 ]
Shah, Manish A. [2 ]
Tagawa, Scott [2 ]
Picozzi, Vincent J. [4 ]
Thomas, Sajeve S. [5 ]
Maliakal, Pius P. [6 ]
Wegener, William A. [6 ]
Sharkey, Robert M. [6 ]
Govindan, Serengulam V. [6 ]
Goldenberg, David M. [6 ]
机构：
[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA
[2] NewYork Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
[3] Christiana Care Hlth Syst Graham Canc Ctr, Newark, DE USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] MD Anderson Canc Ctr Orlando, Orlando, FL USA
[6] Immunomedics Inc, Morris Plains, NJ USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C67
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C67
引用
收藏
页数：2
相关论文
共 26 条
  • [1] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Vahdat, Linda T.
    Isakoff, Steven J.
    Guarino, Michael
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Mayer, Ingrid A.
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER, 2017, 123 (19) : 3843 - 3854
  • [2] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Trisal, Preeti
    Arrojo, Roberto
    Liu, Donglin
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Goldenberg, David M.
    BIOCONJUGATE CHEMISTRY, 2015, 26 (05) : 919 - 931
  • [3] Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Starodub, A. N.
    Moroose, R. L.
    Isakoff, S. J.
    Ocean, A. J.
    Guarino, M. J.
    Berlin, J. D.
    Messersmith, W. A.
    Thomas, S. S.
    O'Shaughnessy, J. A.
    Kalinsky, K.
    Maurer, M.
    Chang, J. C.
    Forero, A.
    Traina, T.
    Gucalp, A.
    Wilhelm, F.
    Wegener, W. A.
    Maliakal, P.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2016, 76
  • [4] Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
    Chang, Chien-Hsing
    Wang, Yang
    Zalath, Maria
    Liu, Donglin
    Cardillo, Thomas M.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1910 - 1919
  • [5] Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
    Guarino, Michael J.
    Starodub, Alexander
    Masters, Gregory A.
    Heist, Rebecca Suk
    Messersmith, Wells A.
    Bardia, Aditya
    Ocean, Allyson J.
    Thomas, Sajeve Samuel
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results
    Camidge, D. R.
    Starodub, Aleander N.
    Ocean, Allyson
    Messersmith, Wells A.
    Bardia, Aditya
    Thomas, Sajeve S.
    Masters, Gregory
    Heist, Rebecca
    Maliakal, Pius
    Govindan, Serengulam
    Sharkey, Robert M.
    Wilhelm, Francois E.
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S173 - S173
  • [7] Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
    Goldenberg, David M.
    Rossi, Edmund A.
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    McBride, William J.
    Zalath, Maria
    Terracina, Gaby
    Trisal, Preeti
    Sharkey, Robert M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Treatment for metastatic platinum resistant urothelial cancer (PRUC) with an anti-Trop2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
    Tagawa, Scott T.
    Faltas, Bishoy
    Lam, Elaine
    Messersmith, Wells A.
    Saylor, Philip
    Bardia, Aditya
    Hajdenberg, Julio J.
    Morgans, Alicia K.
    Berlin, Jordan D.
    Lim, Emerson
    Kalinsky, Kevin
    Maliakal, Pius
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Ocean, Allyson J.
    CANCER RESEARCH, 2016, 76
  • [9] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Starodub, Alexander N.
    Shah, Nikita C.
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Guarino, Michael
    Abramson, Vandana
    Juric, Dejan
    Tolaney, Sara M.
    Berlin, Jordan
    Messersmith, Wells A.
    Ocean, Allyson J.
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +
  • [10] IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
    Starodub, Alexander
    Ocean, Allyson J.
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Salim Samuel
    Messersmith, Wells A.
    Shah, Manlsh A.
    Vandat, Linda T.
    Chuang, Ellen
    Lin, Bruce S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
123